Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis

Journal of the American Academy of Dermatology

Volumn 56, Issue 4, 2007, Pages 612-616

  Solomon, Michal ^a,c   Baum, Sharon ^a,c   Barzilai, Aviv ^a,c   Scope, Alon ^a,c   Trau, Henry ^a,c   Schwartz, Eli ^b,c  

^a Department of Dermatology ^*

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; HYDROCORTISONE; STIBOGLUCONATE SODIUM;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; BOLIVIA; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; DYSPNEA; FEMALE; FLUSHING; FOLLOW UP; HOSPITAL CARE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LEISHMANIA BRAZILIENSIS; MALE; OUTPATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SIDE EFFECT; SKIN LEISHMANIASIS; TRAVEL; TREATMENT FAILURE;

ADULT; AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, INFECTIOUS; TREATMENT OUTCOME;

EID: 33947168317     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.06.044     Document Type: Article

References (19)

1. Schwartz E., Hatz C., and Blum J. New World cutaneous leishmaniasis in travellers. Lancet Infect Dis 6 (2006) 342-349
2. Moschella S.L., and Cropley T.G. Diseases of the mononuclear phagocytic system. In: Moschella S.L., and Hurley H.J. (Eds). Dermatology (1992), Saunders, Philadelphia 1115-1127
3. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
4. Scope A., Trau H., Andres G., Barzilai A., Confino Y., and Schwartz E. Experience with New World cutaneous leishmaniasis in travelers. J Am Acad Dermatol 49 (2003) 672-678
5. Lerner E.A., and Grevelink S.A. Leishmaniasis. In: Arndt K.A., LeBoit P.E., Robinson J.K., and Wintroub B.U. (Eds). Cutaneous medicine and surgery (1996), Saunders, Philadelphia 1163-1170
6. Herwaldt B.L., and Berman J.D. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Hyg 46 (1992) 296-306
7. Amato V., Amato J., Nicodemo A., Uip D., Amato-Neto V., and Duarte M. Treatment of mucocutaneous leishmaniasis with pentamidine isothionate. Ann Dermatol Venereol 125 (1998) 492-495
8. Schonian G., Nasereddin A., Dinse N., Schweynoch C., Schallig H.I.D., Presber W., et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diagn Microbiol Infect Dis 47 (2003) 349-358
9. Aronson N.E., Wortmann G.W., Johnson S.C., Jackson J.E., Gasser Jr. R.A., Magill A.J., et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis 27 (1998) 1457-1464
10. El Hajj L., Thellier M., Carriere J., Bricaire F., Danis M., and Caumes E. Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol 43 (2004) 120-125
11. Lawn S.D., Armstrong M., Chilton D., and Whitty C.J. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 100 (2006) 264-269
12. Blum J., Desjeux P., Schwartz E., Beck B., and Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53 (2004) 158-166
13. Minodier P., Retornaz K., Horelt A., and Garnier J.M. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundam Clin Pharmacol 17 (2003) 183-188
14. Musa A.M., Khalil E.A., Mahgoub F.A., Hamad S., Elkadaru A.M., and El Hassan A.M. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann Trop Med Parasitol 99 (2005) 563-569
15. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Gaeta G.B., Pempinello R., et al. Short-course treatment of visceral leishmaniasis with liposomal Amphotericin B (AmBisome). Clin Infect Dis 22 (1996) 938-943
16. Brown M., Noursadeghi M., Boyle J., and Davidson R.N. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 153 (2005) 203-205
17. Amato V.S., Rabello A., Rotondo-Silva A., Kono A., Maldonado T.P., Alves I.C., et al. Successful treatment of cutaneous leishmaniasis with lipid formulation of amphotericin B in two immunocompromised patients. Acta Trop 92 (2004) 127-132
18. Yardley V., and Croft S. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 41 (1997) 752-756
19. Wortmann G.W., Fraser S.L., Aronson N.E., Davis C., Miller R.S., Jackson J.D., et al. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis 26 (1998) 1006-1007